Pyxis Oncology, Inc. (PYXS): Price and Financial Metrics
GET POWR RATINGS... FREE!
PYXS Stock Price Chart Interactive Chart >
PYXS Price/Volume Stats
|Current price||$2.49||52-week high||$19.00|
|Prev. close||$2.44||52-week low||$1.96|
|Day high||$2.51||Avg. volume||135,646|
|50-day MA||$3.20||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||81.71M|
Pyxis Oncology, Inc. (PYXS) Company Bio
Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Most Popular Stories View All
PYXS Latest News Stream
|Loading, please wait...|
PYXS Latest Social Stream
View Full PYXS Social Stream
Latest PYXS News From Around the Web
Below are the latest news stories about Pyxis Oncology Inc that investors may wish to consider to help them evaluate PYXS as an investment opportunity.
Quite a few insiders invested in Pyxis Oncology, Inc. (NASDAQ:PYXS) last year which is positive news for shareholders
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Gainers: Dogness (DOGZ) +17%, Axcelis Technologies (ACLS) +6%, Latch (LTCH) +5%, Faraday Future Intelligent Electric (FFIE) +3%, BigCommerce (BIGC) +3%.Losers: Pyxis
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that the company will be added to the Russell 2000® Index, effective after the U.S. market opens on December 20, 2021, according to the preliminary list of IPO additions to the Russell indexes. Membership in the Russell 2000 Index, which remains in place until the next reconstitution, is based on membership in the broad-market Russell 3000® Index. The stock will also be automatically added to the appropriate growth and value indexes.
Pyxis Oncology Inc (NASDAQ:PYXS) Director Darren S. Cline bought 10,000 shares of the companys stock in a transaction dated Wednesday, December 8th. The stock was bought at an average price of $9.39 per share, for a total transaction of $93,900.00. The transaction was disclosed in a document filed with the SEC, which is available at 
Industry veteran brings expertise in corporate strategy and business development to Pyxis teamCAMBRIDGE, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer. Ms. Molsbergen will be responsible for managing the Company’s current partnerships and joint ventures as well as exploring new business development opportunities. “We are thrilled to welcome Martina to the Pyxis team as interim c
PYXS Price Returns